Search

Displaying results 1111 - 1120 of 3917 in total
  1. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.

  2. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

    Categories: Beta Blocking Agents, Non-Selective
  3. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies. … L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted on

  4. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    It has a weak inhibitory effect on GABA receptor binding sites.

  5. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.

  6. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  7. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium

  8. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

    Categories: Bone Density Conservation Agents
  9. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

    Mixtures: Joint Bone Care
  10. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010.